[1]Toro L, Barrientos V, Leon P, et al.Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury[J].Kidney Int, 2018, 93(5):1131-1141
[2]Daryadel A, Bettoni C, Haider T, et al.Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men[J].Pflugers Arch, 2018, 470(10):1569-1582
[3]Martin A, David V, Quarles L D.Regulation and function of the FGF23klotho endocrine pathways[J].Physiol Rev, 2012, 92(1):131-155
[4]Olauson H, Lindberg K, Amin R, et al.Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion[J].PLoS Genet, 2013, 9(12):e1003975-e1003975
[5]Farrow E G, Yu X, Summers L J, et al.Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice[J].Proc Natl Acad Sci U S A, 2011, 108(46):E1146-E1155
[6]David V, Martin A, Isakova T, et al.Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production[J].Kidney Int, 2016, 89(1):135-146
[7]Fishbane S, Spinowitz B.Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018[J].Am J Kidney Dis, 2018, 71(3):423-435
[8]Ho B B, Bergwitz C.FGF23 signalling and physiology[J].J Mol Endocrinol, 2021, 66(2):R23-R32
[9]Kaplan J M, Sharma N, Dikdan S.Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease[J].Int J Mol Sci, 2018, 19(2):389-389
[10]Del V L, Locatelli F.Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease[J].Expert Opin Investig Drugs, 2018, 27(7):613-621
[11]Bianchi L, Tacchini L, Cairo G.HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation[J].Nucleic Acids Res, 1999, 27(21):4223-4227
[12]Coe L M, Madathil S V, Casu C, et al.FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis[J].J Biol Chem, 2014, 289(14):9795-9810
[13]Rabadi S, Udo I, Leaf D E, et al.Acute blood loss stimulates fibroblast growth factor 23 production[J].Am J Physiol Renal Physiol, 2018, 314(1):F132-F139
[14]Flamme I, Ellinghaus P, Urrego D, et al.FGF23 expression in rodents is directlyinduced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase[J].PLoS One, 2017, 12(10):e186979-e186979
[15]Wolf M, Koch T A, Bregman D B.Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women[J].J Bone Miner Res, 2013, 28(8):1793-1803
[16]Takeda Y, Komaba H, Goto S, et al.Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients[J].Am J Nephrol, 2011, 33(5):421-426
[17] Portoles J, Martin L, Broseta J J, et al.Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents.[J].Front Med (Lausanne), 2021, 8(1):642296-642296
[18]Patino E, Doty S B, Bhatia D, et al.Carbonyl iron and iron dextran therapies cause adverse effects on bone health in juveniles with chronic kidney disease[J].Kidney Int, 2020, 98(5):1210-1224
[19]Haase V H.Regulation of erythropoiesis by hypoxia-inducible factors[J].Blood Rev, 2013, 27(1):41-53
[20]Noonan M L, Clinkenbeard E L, Ni P, et al.Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor(HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)[J].Physiol Rep, 2020, 8(11):e14434-e14434
[21]Durlacher-Betzer K, Hassan A, Levi R, et al.Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease[J].Kidney Int, 2018, 94(2):315-325
[22]Egli-Spichtig D, Imenez S P, Glaudemans B, et al.Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation[J].Kidney Int, 2019, 96(4):890-905
[23]Richter M, Lautze H J, Walther T, et al.The failing heart is a major source of circulating FGF23 via oncostatin M receptor activation[J].J Heart Lung ransplant, 2015, 34(9):1211-1214
[24]Munoz M J, Isakova T, Cai X, et al.Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease[J].Kidney Int, 2017, 91(3):711-719
[25]Munoz M J, Isakova T, Ricardo A C, et al.Fibroblast growth factor 23 and Inflammation in CKD[J].Clin J Am Soc Nephrol, 2012, 7(7):1155-1162
[26] El-Hodhod M A, Hamdy A M, Abbas A A, et al.Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease. [J].BMC Gastroenterol, 2012, 12(1):44-44
[27]Singh S, Grabner A, Yanucil C, et al.Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease[J].Kidney Int, 2016, 90(5):985-996
[28]Ferrari S L, Bonjour J P, Rizzoli R.Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men[J].J Clin Endocrinol Metab, 2005, 90(3):1519-1524
[29]Ix J H, Isakova T, Larive B, et al.Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial[J].J Am Soc Nephrol, 2019, 30(6):1096-1108
[30]Cheng S C, Young D O, Huang Y, et al.A randomized,double-blind,placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients[J].Clin J Am Soc Nephrol, 2008, 3(4):1131-1138
[31]Block G A, Rosenbaum D P, Yan A, et al.The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia[J].Nephrol Dial Transplant, 2019, 34(2):339-346
[32]Chertow G M, Block G A, Correa-Rotter R, et al.Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis[J].N Engl J Med, 2012, 367(26):2482-2494
[33]Noonan M L, Ni P, Agoro R, et al.The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model[J].J Bone Miner Res, 2021, 36(6):1117-1130
[34]Francis C, Courbon G, Gerber C, Neuburg S, Wang X, Dussold C, Capella M, Qi L, Isakova T, Mehta R, Martin A, Wolf M, David V.Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in?a?mouse model of chronic kidney disease[J].Kidney Int, 2019, 96(6):1346-1358
[35]Neiser S, Rentsch D, Dippon U, et al.Physico-chemical properties of the newgeneration IV iron preparations ferumoxytol,and ferric carboxymaltose[J].Biometals, 2015, 28(4):615-635
[36]Jahn M R, Andreasen H B, Futterer S, et al.A comparative study of the physicochemical properties of iron isomaltoside 1000(Monofer),a new intravenous iron preparation and its clinical implications[J].Eur J Pharm Biopharm, 2011, 78(3):480-491
[37]Lamb Y N.Burosumab: First Global Approval[J].Drugs, 2018, 78(6):707-714
[38]Grabner A, Faul C.The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy[J].Curr Opin Nephrol Hypertens, 2016, 25(4):314-324
